Copyright © Inderes 2011 - present. All rights reserved.
Regulatory press release

Modus Therapeutics publishes interim report for the first quarter 2024

Modus Therapeutics Holding
Download the release

STOCKHOLM, SWEDEN - 14 May 2024: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the first quarter 2024. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.

John Öhd, Modus Therapeutics' CEO, commented:
” After the financing that Modus Therapeutics carried out in December 2023, the focus in the first quarter of 2024 has been on carrying out planned activities within the research areas that the company deems prioritized; chronic kidney disease with anemia, sepsis and severe malaria. During the quarter, Modus worked intensively on the preparations of the phase IIa study which aims to establish proof-of-concept for the treatment effect of sevuparin in patients with anemia in kidney disease.”

The first quarter in figures

  • The loss after tax amounted to TSEK 3 105 (6 040).
  • The loss per share amounted to SEK 0,09 (0,38).
  • The cash flow from current operations was negative in the amount of TSEK 3 665 (6 335).

Important events during the first quarter

  • Modus Therapeutics participated in Swiss Nordic Bio, Zurich.

Important events after the end of the period
No event to report.

CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid on May 14 at 13:00 Link to Interview: https://www.youtube.com/watch?v=plSUuV2WFdo

For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com

This information is information that Modus Therapeutics Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-14 08:00 CEST.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se

About Modus Therapeutics and sevuparin
Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments
Modus Q1 2024 ENG